Drug intelligence / Profile preview

Remsima SC

Development stage: Unknown
Lead developer: Celltrion
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

Remsima SC is the world's first subcutaneous formulation of biosimilar infliximab, developed by Celltrion. It is a monoclonal antibody that neutralizes tumor necrosis factor-alpha (TNF-alpha), a key mediator in autoimmune diseases. It is approved for various inflammatory conditions including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, and ulcerative colitis. Its subcutaneous administration offers convenience for patients, allowing self-injection and reducing the need for frequent clinic visits.

Brand names: Remsima SC
Other names: Infliximab BiosimilarBiosimilar Infliximab

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on Remsima SC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Remsima SC.

Explore the full profile